All In Biotech

Drug Trial Radar · NCT07286370

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants

A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 537 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

537

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Apr 27, 2028

Study completion Apr 27, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) vaccine in infants with the first dose administered at 6 months of age (MOA) or 6 weeks of age (WOA).

Conditions

  • Salmonella Infections

Interventions

  • Low dose of iNTS-TCVBiological

    Low dose of iNTS-TCV vaccine will be administered.

  • Full dose of iNTS-TCVBiological

    Full dose of iNTS-TCV vaccine will be administered.

  • TYPHIBEVBiological

    TYPHIBEV vaccine will be administered.

  • Prevenar 13Combination product

    Prevenar 13 vaccine will be administered.

  • NimenrixCombination product

    Nimenrix vaccine will be administered.

  • SalineDrug

    Saline will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with solicited administration site events during 7 days after each study intervention administration [for infants 6 MOA]Time frame: At Day 1, Day 85 and Day 337
  2. Number of participants with solicited systemic events during 7 days after each study intervention administration [for infants 6 MOA]Time frame: At Day 1, Day 85 and Day 337
  3. Number of participants with unsolicited adverse events (AEs) during 28 days after each study intervention administration [for infants 6 MOA]Time frame: At Day 1, Day 85 and Day 337
  4. Number of participants with serious adverse events (SAEs) [for infants 6 MOA]Time frame: From the first study intervention administration (Day 1) until study end (Day 505).
  5. Number of participants with AEs/SAEs leading to withdrawal from the study or discontinuation of study intervention [for infants 6 MOA]Time frame: From the first study intervention administration (Day 1) until study end (Day 505).
  6. Number of participants with laboratory abnormalities [for infants 6 MOA]Time frame: At 7 days after each study intervention administration (Day 8, Day 92 and Day 344).
  7. Number of participants with solicited administration site events during 7 days after each study intervention administration [for infants 6 WOA]Time frame: At Day 1, Day 57 and Day 232
  8. Number of participants with solicited systemic events during 7 days after each study intervention administration [for infants 6 WOA]Time frame: At Day 1, Day 57 and Day 232
  9. Number of participants with unsolicited adverse events (AEs) during 28 days after each study intervention administration [for infants 6 WOA]Time frame: At Day 1, Day 57 and Day 232
  10. Number of participants with SAEs [for infants 6 WOA]Time frame: From the first study intervention administration (Day 1) until study end (Day 400).
  11. Number of participants with AEs/SAEs leading to withdrawal from the study or discontinuation of study intervention [for infants 6 WOA]Time frame: From the first study intervention administration (Day 1) until study end (Day 400).
  12. Number of participants with laboratory abnormalities [for infants 6 WOA]Time frame: At 7 days after each study intervention administration (Day 8, Day 64 and Day 239).
  13. Geometric Mean concentration (GMC) ratio of anti- S. typhimurium (STm) and anti- Salmonella Enteritidis (SEn) O-antigen (OAg) immunoglobulin G (IgG) [for infants 6 MOA]Time frame: At 28 days after the second study intervention administration (Day 113)
  14. GMC ratio of anti-Vi IgG [for infants 6 MOA]Time frame: At 28 days after the first study intervention administration (Day 29)
  15. GMC ratio of anti-STm and anti-SEn OAg IgG concentrations [for infants 6 WOA]Time frame: At 28 days after the third study intervention administration (Day 260)
  16. GMC ratio of anti-Vi IgG [for infants 6 WOA]Time frame: At 28 days after the third study intervention administration (Day 260)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Banjul, The Gambia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.